Tirzepatide is a once-weekly injectable peptide that simultaneously activates two incretin receptors: GLP-1R (glucagon-like peptide-1 receptor) and GIPR (glucose-dependent insulinotropic polypeptide receptor). Every approved GLP-1 drug before tirzepatide (semaglutide, liraglutide, dulaglutide) is a single-receptor GLP-1 agonist. Tirzepatide is the first dual incretin — and the SURMOUNT and SURPASS trial series demonstrates that the GIP receptor component adds substantially to weight loss outcomes beyond GLP-1 alone, producing the first pharmaceutical results approaching surgical weight loss in magnitude.
The mechanism of GIP receptor agonism in weight loss was counterintuitive: GIP was historically considered to promote fat storage (it's released after meals and stimulates insulin secretion), and early logic suggested blocking GIPR, not activating it, would be beneficial for obesity. Tirzepatide's development reversed this hypothesis — at supraphysiological doses achieved by injectable peptides, GIPR agonism appears to produce central appetite suppression and peripheral fat metabolism that synergizes with GLP-1R agonism rather than opposing it. The exact mechanism remains an active research area.
| Feature | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Drug class | Dual GIP+GLP-1 receptor agonist (the first) | GLP-1 receptor agonist (selective) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| T2D brand | Mounjaro (max 15mg weekly) | Ozempic (max 2mg weekly) |
| Obesity brand | Zepbound (max 15mg weekly) | Wegovy (max 2.4mg weekly) |
| Mean weight loss | 20.9% at 15mg (SURMOUNT-1) — 47% more than semaglutide in head-to-head (SURMOUNT-5) | 14.9% at 2.4mg (STEP 1 — Wilding 2021 NEJM N=1,961) |
| % achieving ≥20% loss | 63% at 15mg (SURMOUNT-1) | ~32% at 2.4mg (STEP 1) |
| Cardiovascular outcomes | SURPASS-CVOT (2023): 14% MACE reduction in T2D with CVD (non-inferior to standard of care; superiority trial ongoing for obesity indication) | SELECT (2023): 20% MACE reduction in non-diabetic CVD patients (Lincoff NEJM); Ozempic LEADER: 13% MACE reduction in T2D |
| Dosing schedule | Once weekly SC injection; titration: 2.5mg × 4 weeks, increase by 2.5mg every 4 weeks to maintenance (max 15mg) | Once weekly SC injection; titration: 0.25mg × 4 weeks then escalate; Wegovy: slower titration to 2.4mg over 68 weeks |
| List price (US, 2026) | Mounjaro ~$1,023/month; Zepbound ~$1,060/month; Lilly savings card ~$550/month for commercially insured | Ozempic ~$936/month; Wegovy ~$1,349/month; Novo savings programs available |
| GI side effects | Nausea 20–35%, vomiting 8–12%, diarrhea 12–15% (similar profile to semaglutide, possibly slightly better tolerated in some comparisons) | Nausea 20–40%, vomiting 8–18%, diarrhea 8–20% (dose-dependent; worse during titration) |
| Muscle loss risk | ~30–40% of weight loss from lean mass loss without resistance training — same concern as all GLP-1 class drugs | ~30–40% lean mass loss without resistance training (Wilding 2021 NEJM body composition substudy) |
SURMOUNT-5 (2024) was the long-awaited direct comparison. Participants with obesity (BMI ≥30 or ≥27+comorbidity, without T2D) were randomized to tirzepatide 10 or 15mg or semaglutide 2.4mg for 72 weeks. Results: mean body weight reduction 20.2% (tirzepatide) vs 13.7% (semaglutide); 47% greater relative weight reduction; at ≥25% weight loss: tirzepatide 32% vs semaglutide 16%; at ≥20% weight loss: tirzepatide 52% vs semaglutide 33%. GI tolerability was similar between groups. SURMOUNT-5 established tirzepatide as the more potent weight loss agent in a direct head-to-head comparison — though semaglutide remains highly effective and may be preferred in specific populations (the SELECT cardiovascular outcomes data for semaglutide in non-diabetic CVD patients has no equivalent tirzepatide data yet).
Starting dose: 2.5mg weekly SC injection (abdomen, thigh, or upper arm; rotate sites). Auto-injector pens are pre-filled and single-use. Refrigerate; bring to room temperature 30 minutes before injection. First dose under medical supervision recommended but not always required.
Titration: Increase by 2.5mg every 4 weeks: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Slower titration (staying at each dose 6–8 weeks instead of 4) significantly reduces nausea. Many patients achieve sufficient results at 10mg and do not need 15mg. Don't rush titration for a number on the label — slower titration = better tolerability = better adherence.
GI side effect management: Eat smaller portions; avoid high-fat, high-sugar meals (particularly within 2 hours of injection); stay hydrated; ginger tea or ginger candies for nausea; over-the-counter ondansetron (if prescribed) for severe nausea; consider 8-week titration intervals if symptoms are limiting. Nausea almost always improves after 2–4 weeks at each dose level.
Muscle loss mitigation (critical): Resistance training 3× per week minimum is not optional — it is the clinical recommendation with all GLP-1 class drugs including tirzepatide. Without resistance training, 30–40% of weight lost is lean mass. With training, the ratio shifts toward fat loss. Protein intake: ≥1.2g per kg body weight daily (some protocols recommend 1.6g/kg). Consider creatine monohydrate 3–5g/day to preserve strength and muscle mass during weight loss.
Contraindications: Personal/family history of medullary thyroid carcinoma or MEN2 syndrome (class contraindication for all GLP-1 drugs); pancreatitis history (relative contraindication — discuss with physician); pregnancy (discontinue ≥2 months before planned conception). Gallbladder disease: rapid weight loss from any cause increases gallstone risk; tirzepatide increases this risk; consider UDCA supplementation and monitoring in high-risk patients.